Favipiravir intermediate 6-bromo-3-hydroxypyrazine-2-carboxamide

Min.Order / FOB Price:Get Latest Price

1 Gram	Negotiable

1 Gram

Negotiable

Min.Order :1 Gram
Purity: >95%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Favipiravir intermediate efficiency for covid-19 6-bromo-3-hydroxypyrazine-2-carboxamide

Quick Details

Appearance:
Application:efficienct for for COVID-19
PackAge:
ProductionCapacity:hundreds of|Kilogram|Month
Storage:
Transportation:by sea or by air

Superiority:

Fapiravir shows antiviral activity by inhibiting RNA polymerase associated with influenza virus replication. Preclinical pharmacodynamics show that it shows antiviral activity not only against seasonal influenza viruses, but also against various influenza viruses of swine origin and highly pathogenic avian influenza, and does not show significant cross-resistance to existing drug-resistant cell lines Medicinal properties; combination therapy with oseltamivir has shown a synergistic effect on influenza viruses. Clinical studies have shown that fapiravir and oseltamivir have similar efficacy. Preclinical toxicology has only been found in female animals in reproductive toxicity experiments. Pilavivir leads to early embryonic death and fetal teratogenicity. Therefore, it is recommended that pregnant women and women who are likely to become pregnant should ban the use of piriravir in principle. It is effective against a variety of subtypes of avian influenza viruses, such as H1N1, H5N1 and H7N9, etc., and can also inhibit the transcription of other viruses, such as sand virus, yellow fever virus, West Nile disease, viral Bunia virus and hand-foot-mouth virus It can also effectively inhibit Zairian Ebola virus RNA replication (IC90 is 110 mol/L). Therefore, it is a brand-new antiviral drug with definite curative effect and good safety mechanism, and has good application prospects.

View All

Visit Store